AU2001251138A1 - Compositions and methods for tissue specific gene regulation therapy - Google Patents
Compositions and methods for tissue specific gene regulation therapyInfo
- Publication number
- AU2001251138A1 AU2001251138A1 AU2001251138A AU5113801A AU2001251138A1 AU 2001251138 A1 AU2001251138 A1 AU 2001251138A1 AU 2001251138 A AU2001251138 A AU 2001251138A AU 5113801 A AU5113801 A AU 5113801A AU 2001251138 A1 AU2001251138 A1 AU 2001251138A1
- Authority
- AU
- Australia
- Prior art keywords
- compositions
- methods
- specific gene
- tissue specific
- gene regulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19397700P | 2000-03-31 | 2000-03-31 | |
US60/193,977 | 2000-03-31 | ||
PCT/US2001/010250 WO2001074861A2 (en) | 2000-03-31 | 2001-03-30 | Compositions and methods for tissue specific gene regulation therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001251138A1 true AU2001251138A1 (en) | 2001-10-15 |
Family
ID=22715820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001251138A Abandoned AU2001251138A1 (en) | 2000-03-31 | 2001-03-30 | Compositions and methods for tissue specific gene regulation therapy |
Country Status (3)
Country | Link |
---|---|
US (1) | US20020150556A1 (en) |
AU (1) | AU2001251138A1 (en) |
WO (1) | WO2001074861A2 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020187543A1 (en) * | 2001-04-05 | 2002-12-12 | Curiel David T. | Enhanced dispersion of adenoviral vectors by fusogenic membrane glycoproteins |
US20040009604A1 (en) * | 2002-03-27 | 2004-01-15 | Xiaoliu Zhang | Potent oncolytic herpes simplex virus for cancer therapy |
GB0415963D0 (en) * | 2004-07-16 | 2004-08-18 | Cxr Biosciences Ltd | Detection of cellular stress |
WO2016154299A1 (en) * | 2015-03-24 | 2016-09-29 | The Trustees Of Columbia University In The City Of New York | Genetic modification of pigs for xenotransplantation |
US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
EP3235908A1 (en) | 2016-04-21 | 2017-10-25 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
BR112019023323A2 (en) | 2017-05-08 | 2020-07-21 | Flagship Pioneering Innovations V, Inc. | compositions to facilitate membrane fusion and uses thereof |
CN109381701A (en) * | 2017-08-11 | 2019-02-26 | 复旦大学 | Promotion sensitivity gene JCAD and its as target spot preparation treatment liver cancer drug in purposes |
BR112021000145A2 (en) * | 2018-07-09 | 2021-04-06 | Flagship Pioneering Innovations V, Inc | FUSOSOME COMPOSITIONS AND USES OF THE SAME |
AU2022253020A1 (en) | 2021-04-08 | 2023-10-26 | Shirisha AMATYA | Cd8-specific antibody constructs and compositions thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4422804B2 (en) * | 1997-03-11 | 2010-02-24 | メイヨー・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | Compositions and methods for eliminating unwanted cells |
DE19834430C2 (en) * | 1998-07-30 | 2000-05-31 | Harald Von Melchner | Self-deleting vectors for cancer therapy |
GB9825429D0 (en) * | 1998-11-20 | 1999-01-13 | Medical Res Council | Fusion hybrids expressing fusogenic membrane glycoproteins |
-
2001
- 2001-03-30 AU AU2001251138A patent/AU2001251138A1/en not_active Abandoned
- 2001-03-30 WO PCT/US2001/010250 patent/WO2001074861A2/en active Application Filing
- 2001-03-30 US US09/822,634 patent/US20020150556A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020150556A1 (en) | 2002-10-17 |
WO2001074861A9 (en) | 2002-12-27 |
WO2001074861A3 (en) | 2002-03-14 |
WO2001074861A2 (en) | 2001-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002332020A1 (en) | Compositions for oral gene therapy and methods of using same | |
AU4193700A (en) | Antisense oligonucleotide compositions and methods for the modulation of jnk proteins | |
AU2003200740A1 (en) | Compositions and methods for the treatment of tumor | |
AU2003200731A1 (en) | Compositions and methods for the treatment of tumor | |
AU2003200722A1 (en) | Compositions and methods for the treatment of tumor | |
AU2495200A (en) | Compositions and methods for the treatment of tumor | |
AU2001260847A1 (en) | Compositions isolated from skin cells and methods for their use | |
AU2001245987A1 (en) | Compositions and methods for gene therapy | |
AU2002223593A1 (en) | Regulation of human sphingosine kinase-like protein | |
AU2001251138A1 (en) | Compositions and methods for tissue specific gene regulation therapy | |
AU1723001A (en) | Methods and means for regulation of gene expression | |
AU6094200A (en) | Nor gene compositions and methods for use thereof | |
AU2001269077A1 (en) | Methods and means for regulation of gene expression | |
AU2001255730A1 (en) | Methods and compositions for the treatment of cardiac indications | |
AU2000231423A1 (en) | Specific therapeutic composition for treating aids | |
AU2001253528A1 (en) | Methods and compositions for culturing spirochetes and treating spirochetal diseases | |
AU2001281950A1 (en) | Regulation of human thimet oligopeptidase-like enzyme | |
AU2001253469A1 (en) | Compositions and methods for stabilizing modified tissue | |
AU2001274080A1 (en) | Regulation of human transketolase-like enzyme | |
AU2002231620A1 (en) | Regulation of human patched-like protein | |
AU2002215956A1 (en) | Regulation of human pgc-1-like protein | |
AU2002210525A1 (en) | Regulation of human phospholipase-like enzyme | |
AU2001285782A1 (en) | Regulation of human phosphodiesterase-like enzyme | |
AU2002215942A1 (en) | Regulation of human carboxylesterase-like enzyme | |
AU2001281969A1 (en) | Regulation of human carboxylesterase-like enzyme |